Diagnosis and treatment of Helicobacter pylori
Tóm tắt
Helicobacter pylori infection remains a ubiquitous infection, especially in populations with poor socioeconomic conditions. Severe clinical outcomes of chronic infection include peptic ulcer disease and gastric cancer. Consensus meetings have developed guidelines for diagnosis, treatment, and management of H. pylori infection and related disorders in various populations. Clear benefits are obtained for H. pylori eradication in peptic ulcer disease and gastric mucosa-associated lymphoid tissue lymphoma. Most authorities agree that first-degree relatives of gastric cancer patients should undergo testing for H. pylori infection. H. pylori eradication in dyspepsia remains controversial. Global investigations continue to identify specific host and bacterial factors that are responsible for H. pylori-related inflammatory processes and development of clinical disease. Effective eradication regimens have been identified. The proton pump inhibitor (PPI)-based triple therapies are considered first-line therapy because of high patient compliance and good eradication rates. “Quadruple therapy” with bismuth-metronidazoletetracycline plus a PPI is another first-line therapy with a similar eradication rate. This therapy is preferred in patients with penicillin allergy or prior exposure to clarithromycin. Rescue regimens are being developed because of rising antimicrobial resistance to metronidazole and clarithromycin in H. pylori strains. Emerging rescue combination therapies include furazolidone, rifabutin, and quinolones. These combination regimens are still preliminary and should be reserved for patients who have failed first-line therapies. Vaccine development remains elusive.
Tài liệu tham khảo
Suerbaum S, Michetti P: Helicobacter pylori infection. N Engl J Med 2002, 347: 1175–1186. This is an excellent discussion of H. pylori infection, its disease relationships, and future challenges with this infection.
The Eurogast Study Group: Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut 1993, 34: 1672–1676.
Go MF: Epidemiology and natural history of H. pylori. Aliment Pharmacol Ther 2002, 16(Suppl 1):3–15.
Vakil N, Vaira D: Non-invasive tests for the diagnosis of H. pylori infection. Rev Gastroenterol Dis 2004, 4: 1–6.
Gisbert JP, Pajares JM: Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004, 9: 347–368.
Gatta L, Perna F, Ricci C, et al.: A rapid immunochromatographic assay for Helicobacter pylori in stool before and after treatment. Aliment Pharmacol Ther 2004, 20: 469–474.
Gatta L, Vakil N, Ricci C, et al.: Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004, 99: 823–829.
NIH Consensus Conference: Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994, 272: 65–69.
Peura DA: The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology 1997, 113 (suppl):S4-S8.
Howden CW, Hunt RH: Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998, 93: 2330–2338.
Malfertheiner P, Megraud F, O’Morain C, et al. and the European Helicobacter Pylori Study Group (EHPSG): Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002, 16: 167–180.
Asaka M, Satoh K, Sugano K, et al.: Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 2001, 6: 177–186.
Coelho LG, Leon-Barua R, Quigley EM: Latin-American consensus conference on Helicobacter pylori infection. Latin-American national gastroenterological societie affiliated with the Inter-American Association of Gastroenerologie (AIGE). Am J Gastroenterol 2000, 95: 2688–2691.
HuntR, Fallone C, van Zanten SV, et al.: Canadian Helicobacter study group consensus conference: update on the management of Helicobacter pylori—an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can J Gastroenterol 2004, 18: 547–554. Very current, evidence-based guidelines on H. pylori diagnosis, eradication treatment, and management approaches for primary and specialty care.
HuangJQ, Sridhar S, Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359: 14–22. This important study discusses the important roles of H. pylori and NSAIDs in peptic ulcer pathogenesis and peptic ulcer bleeding.
Hopkins RJ, Girardi LS, Turney EA: Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review. Gastroenterology 1996, 110: 1244–1252.
Laine L, Sugg J: Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002, 97: 2992–2997.
Raghunath AS, Hungin AP, Wooff D, Childs S: Systematic review: the effect of Helicobacter pylori and its eradication on gastro-esophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004, 20: 733–744.
Harvey RF, Lane JA, Murray LJ, et al.: Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-esophageal reflux: Bristol helicobacter project. BMJ 2004, 12:328: 1417.
Holtmann G, Cain C, Malfertheiner P: Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterol 1999, 117: 11–16.
Vakil NB, Traxler BM, Levine D: Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 2004, 99: 1437–1441.
De Wit NJ, De Boer WA, Geldof H, et al.: Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? Aliment Pharmacol Ther 2004, 20: 451–458.
Huang JQ, Sridhar S, Chen Y, Hunt RH: Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998, 114: 1169–1179.
International Agency for Research on Cancer: Schistosomes, liver flukes and Helicobacter pylori. In IARC Monographs Programme on the Evaluation of Carcinogenic Risks to Humans, vol 61. France: IARC; 1994.
A The Eurogast Study Group: An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993, 34: 1359–1362.
Uemura N, Okamoto S, Yamamoto S, et al.: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001, 345: 784–789.
El-Omar EM, Carrington M, Chow WH, et al.: Interleukin-1 polymorphism associated with increased risk of gastric cancer. Nature 2000, 404: 398–402.
El-Omar EM, Rabkin CS, Gammon MD, et al.: Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003, 124: 1193–1201.
Talley NJ, Silverstein MD, Agreus L, et al.: AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998, 114: 582–595.
Chey WD, Moayyedi P: Uninvestigated dyspepsia and non-ulcer dyspepsia—the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy. Aliment Pharmacol Ther 2004, 19 (Suppl 1):1–8.
Chiba N, Van Zanten SJ, Sinclair P, et al.: Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002, 324: 1012–1016.
Moayyedi P, Feltbower R, Brown J, et al.: Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. Lancet 2000, 355: 1665–1669.
Laine L, Schoenfeld P, Fennerty MB: Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001, 134: 361–369.
Moayyedi P, Deeks J, Talley NJ, et al.: An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003, 98: 2621–2626.
Sreedharan A, Clough M, Hemingbrough E, et al.: Costeffectiveness and long-term impact of Helicobacter pylori “test and treat” service in reducing open access endoscopy referrals. Eur J Gastroenterol Hepatol 2004, 16: 981–986.
Goodman KJ, Correa P, Tengana Aux HJ, et al.: Helicobacter pylori infection in the Colombian Andes: a population-based study of transmission pathways. Am J Epidemiol 1996, 144: 290–299.
Correa P, Fontham ET, Bravo JC, et al.: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000, 92: 1881–1888.
Wang K-Y, Li S-N, Liu C-S, et al.: Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr 2004, 80: 737–741.
Johnson-Henry KC, Mitchell DJ, Avitzur Y, et al.: Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci 2004, 49: 1095–1102.
Joossens JV, Hill MJ, Elliott P, et al.: Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. Int J Epidemiol 1996, 25: 494–504.
Murray LJ, Lane AJ, Harvey IM, et al.: Inverse relationship between alcohol consumption and active Helicobacter pylori infection: the Bristol Helicobacter project. Am J Gastroenterol 2002, 97: 2750–2755.
Baena JM, Lopez C, Hidalgo A, et al.: Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Eur J Gastroenterol Hepatol 2002, 14: 291–296.
VakilN, Lanza F, Schwartz H, Barth J: Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004, 20: 99–107. This is the first successful 7-day H. pylori treatment regimen approved by the FDA.
Juang JQ, Hunt RH: The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999, 13: 719–729.
McMahon BJ, Hennessy TW, Bensler JM, et al.: The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003, 139: 463–469.
Meyer JM, Silliman NP, Wang W, et al.: Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med 2002, 136: 13–24.
LaineL, Hunt R, El-Zimaity H, et al.: Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003, 98: 562–567. This study confirmed that a bismuth-containing combination therapy can eradicate or “overcome” H. pylori strains with metronidazole resistance. It should be noted that omeprazole was prescribed twice daily in this 10-day treatment regimen.
Perri F, Festa V, Clemente R, et al.: Rifabutin-based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000, 14: 311–316.
Pilotto A, Franceschi M, Rassu M, et al.: In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. Am J Gastroenterol 2000, 95: 833–834.
Gisbert JP, Pajares JM: Helicobacter pylori “rescue” regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002, 16: 1047–1057.
Graham DY, Osato M, Hoffman J, et al.: Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000, 14: 211–215.
Fakheri H, Merat S, Hosseini V, Malekzadeh R: Lowdose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004, 19: 89–93.
Bosques-Padilla FJ, Garza-Gonzalez E, Calderon-Lozano I, et al.: Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication: 7 vs 14 day treatment. Helicobacter 2004, 9: 417–421.
Gatta L, Ricci C, Zulla A, et al.: High eradication rate with a rescue levofloxacin based treatment for Helicobacter pylori [Abstract]. Gastroenterol 2004, 126: A74.
Michetti P, Svennerholm AM: Helicobacter pylori-inflammation, immunity and vaccines. Helicobacter 2003, 9 (Suppl 1):31–35.